Search Results - "Arumugham, Thangam"

Gabapentin Enacarbil and Morphine Administered in Combination Versus Alone: A Double-blind, Randomized, Pharmacokinetic, and Tolerability Comparison by Chen, Chao, PhD, Upward, James, MBBS, Arumugham, Thangam, PhD, Stier, Brendt, MS, Davy, Maria, PhD

“…Abstract Purpose Coadministration of morphine with oral gabapentin has been shown to increase plasma gabapentin concentrations. This study evaluated whether…”
Get full text

Cardiac Repolarization With Gabapentin Enacarbil in a Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Thorough QT/QTc Study in Healthy Adults by Davy, Maria, PhD, Upward, James, MB, BS, Arumugham, Thangam, PhD, Twomey, Colleen, MS, Chen, Chao, PhD, Stier, Brendt, MS

“…Abstract Background Gabapentin enacarbil (GEn) is a prodrug of gabapentin and is approved in the United States in adults for the management of postherpetic…”
Get full text

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects by Naderer, Odin, Schuck, Virna, Morrison, Marion, Anderson, Maggie, Arumugham, Thangam, Dunn, John

Get full text

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1 by Dimmitt, Dan C., Choo, Youn Sung, Martin, Lorene A., Arumugham, Thangam, Hahne, William F., Weir, Scott J.

“…In this first part of a two‐part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5‐HT3 receptor antagonist, and the absolute…”
Get full text

Bayesian Methods for Pharmacokinetic/Pharmacodynamic Modeling of Pazopanib-Induced Increases in Blood Pressure and Transaminases by Suttle, A. Benjamin, de Souza, Paul, Arumugham, Thangam

“…Relationships between plasma pazopanib concentrations and the probability of elevations in blood pressure, a marker of vascular endothelial growth factor…”
Get full text

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects by Wire, Mary Beth, Morrison, Marion, Anderson, Maggie, Arumugham, Thangam, Dunn, John, Naderer, Odin

“…Abstract Background BCV is a lipid conjugate nucleotide that has shown rapid viral clearance in patients with adenovirus infection and improved survival in…”
Get full text

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors by de Jonge, Maja J. A., Hamberg, Paul, Verweij, Jaap, Savage, Shawna, Suttle, A. Benjamin, Hodge, Jeffrey, Arumugham, Thangam, Pandite, Lini N., Hurwitz, Herbert I.

“…Summary This phase I, open-label, dose-escalation study assessed the maximum-tolerated dose, safety, pharmacokinetics, and preliminary antitumor activity of…”
Get full text

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors by Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.

“…Purpose. To evaluate the maximum tolerated regimen (MTR), dose‐limiting toxicities, and pharmacokinetics of pazopanib, an oral small‐molecule tyrosine kinase…”
Get full text

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study by Tompson, Debra J, Crean, Christopher S, Buraglio, Mauro, Arumugham, Thangam

“…The potential for ezogabine/retigabine (EZG/RTG) and its N-acetyl metabolite (NAMR) to inhibit the transporter protein P-glycoprotein-(P-gp)-mediated digoxin…”
Get full text

DRUG INTERACTION STUDY OF GR270773 EMULSION AND LEVOFLOXACIN (LEVO) IN HEALTHY VOLUNTEERS: 247-T by Naderer, Odin, Suttle, Ben A, Arumugham, Thangam, Min, Sherene S, Jones, Lori S

Get full text

DRUG INTERACTION STUDY OF GR270773 EMULSION AND PROPOFOL IN HEALTHY VOLUNTEERS: 242-T by Naderer, Odin, Suttle, Ben A, Arumugham, Thangam, Min, Sherene, Jones, Lori S

Get full text

SAFETY AND PHARMACOKINETICS OF GR270773, A NOVEL ANTISEPSIS COMPOUND, IN SEPTIC PATIENTS: 618 by Naderer, Odin J, Suttle, Ben, Denning, Jill, Arumugham, Thangam, Min, Sherene, Parkin, Jackie

Get full text

Curvature and experimental design for the Weibull model by Arumugham, Thangam

“…In this research we address two issues arising in the choice of design points for the Weibull model. The first issue studied is the curvature of the Weibull…”
Get full text

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects by DIMMITT, D. C, CRAMER, M. B, KEUNG, A, ARUMUGHAM, T, WEIR, S. J

“…Dolasetron is a selective 5-HT3 receptor antagonist. The purpose of this study was to determine the effect of cimetidine and rifampin on the steady-state…”
Get full text

Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16 455A) by Stoltz, Maxine, Arumugham, Thangam, Lippert, Christina, Yu, Dale, Bhargava, Vijay, Eller, Mark, Weir, Scott

Get full text

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment by DIMMITT, D. C, SHAH, A. K, ARUMUGHAM, T, CRAMER, M. B, HALSTENSON, C, HORTON, M, WEIR, S. J

“…In an open-label, randomized, two-way complete crossover study, the influence of renal impairment on the pharmacokinetics of dolasetron and its primary active…”
Get full text

Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers by Dimmitt, D C, Bhargava, V O, Arumugham, T, Eller, M, Weir, S J

“…The purpose of this study was to determine the relative bioavailability of Cardizem CD compared to Tiazac after single and multiple doses. Twenty-three healthy…”
Get more information

The effect of food on the bioavailability of dolasetron mesylate tablets by Lippert, Christina, Keung, Anther, Arumugham, Thangam, Eller, Mark, Hahne, William, Weir, Scott

“…Anzemet® (dolasetron mesylate) is being developed for the prevention of chemotherapy‐induced emesis and postoperative nausea and vomiting. Twenty‐four healthy…”
Get full text

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2 by Dimmitt, Dan C., Choo, Youn Sung, Martin, Lorene A., Arumugham, Thangam, Hahne, William F., Weir, Scott J.

“…The single‐ and multiple‐dose pharmacokinetics and dose‐proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was…”
Get full text

Effect of Infusion Rate on the Pharmacokinetics and Tolerance of Intravenous Dolasetron Mesylate by Dimmitt, Dan C, Hunt, Thomas L, Spalitto, Anthony J, Cramer, Michael B, Shah, Ajit K, Arumugham, Thangam, Hahne, William

“…OBJECTIVE To evaluate the safety, tolerance, and pharmacokinetics of dolasetron mesylate and its active metabolite hydrodolasetron when dolasetron mesylate was…”
Get full text